PubMed Journals Articles About "Alphagan Brimonidine Glaucoma" RSS

05:53 EDT 21st August 2018 | BioPortfolio

Alphagan Brimonidine Glaucoma PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest Alphagan Brimonidine Glaucoma articles that have been published worldwide.

More Information about "Alphagan Brimonidine Glaucoma" on BioPortfolio

We have published hundreds of Alphagan Brimonidine Glaucoma news stories on BioPortfolio along with dozens of Alphagan Brimonidine Glaucoma Clinical Trials and PubMed Articles about Alphagan Brimonidine Glaucoma for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Alphagan Brimonidine Glaucoma Companies in our database. You can also find out about relevant Alphagan Brimonidine Glaucoma Drugs and Medications on this site too.

Showing "Alphagan brimonidine Glaucoma" PubMed Articles, all 9

Amino-Functionalized Mesoporous Silica Particles for Ocular Delivery of Brimonidine.

To treat glaucoma, conventional eye drops are often prescribed. However, the eye drops have limited effectiveness as a result of low drug bioavailability due to their rapid clearance from the preocular space. To resolve this, we proposed amino-functionalized mesoporous silica (AMS) particles as delivery carriers of the glaucoma drug, brimonidine. Because of the presence of mesopores, brimonidine (BMD) could be encapsulated in the AMS with a loading amount of 41.73 μg/mg (i.e., drug loading capacity of abou...

Reduction of Ultraviolet B Light-Induced Erythema by Oxymetazoline and Brimonidine Is Mediated by Different α-Adrenoceptors.

When applied topically, oxymetazoline and brimonidine reduce the persistent facial erythema of rosacea; this effect is mediated by cutaneous vasoconstriction induced by postsynaptic activation of α-adrenoceptors. We investigated the α-adrenergic pharmacology of oxymetazoline and brimonidine. Functional activity on α-adrenoceptors was evaluated in vitro in HEK293 cells stably expressing single receptor subtypes using a fluorometric imaging plate reader Ca influx assay. Oxymetazoline was an α -adrenocepto...

The Efficacy and Safety of the Fixed Combination of Brinzolamide 1% and Brimonidine 0.2% in Normal Tension Glaucoma: An 18-Month Retrospective Study.

To evaluate efficacy and safety of brinzolamide (1%)/brimonidine (0.2%) fixed combination (BBFC) in normal tension glaucoma (NTG).

Effect of brimonidine, an α2 adrenergic agonist, on human meibomian gland epithelial cells.

We recently discovered that the anti-glaucoma pharmaceuticals timolol, a β adrenergic antagonist, and pilocarpine, a cholinergic compound, negatively influence the morphology, proliferative capacity and survival of human meibomian gland epithelial cells (HMGECs). We hypothesize that another class of anti-glaucoma drugs, the α2 adrenergic agonists, also acts directly on HMGECs to affect their structure and function. We tested this hypothesis. Immortalized (i) HMGECs were cultured with brimonidine, as well ...


To describe a case of neovascular glaucoma from cytomegalovirus (CMV) retinitis in a human immunodeficiency virus-negative patient with immunosuppression after stem-cell transplant for multiple myeloma.

In Vitro Safety Pharmacology Profiling of Topical α-Adrenergic Agonist Treatments for Erythema of Rosacea.

Topical α-adrenergic agonist therapy has been developed to treat the persistent erythema of rosacea patients. Brimonidine and oxymetazoline are both topical α-adrenergic agonists.


Persistent hyperplastic primary vitreous (PHPV) is a developmental anomaly in which the normal regression of the primary vitreous and hyaloid vasculature does not occur. In the literature, there are a few cases of PHPV in adulthood. We report the novel presentation of phacoanaphylactic glaucoma secondary to posterior capsular rupture in an adult with PHPV. We discuss the best management of this condition with a review of the literature on this topic.

Fifteen Minute Test May Save 15% or More on Rosacea Treatment.

Rosacea is a common inflammatory skin condition that impacts a large portion of fair-skinned populations. The redness associated with rosacea can be a significant challenge. Brimonidine sulfate and oxymetazoline HCL were both recently approved by the FDA for the management of facial redness. These agents, however, are costly, and not all patients respond to the medication. Herein, we describe a clinical pearl that helps to optimize patient selection for the medications. This saves the patient and the health...

Branched polyrotaxane hydrogels consisting of alpha-cyclodextrin and low-molecular-weight four-arm polyethylene glycol and the utility of their thixotropic property for controlled drug release.

In this work, we developed a new class of branched polyrotaxane hydrogel made of 4-arm polyethylene glycol (4-PEG) and α-cyclodextrin (α-CD) using supramolecular host-guest interactions as a cross-linking strategy. Because of the dynamic nature of the non-covalent host-guest cross-linking, the resulting supramolecular α-CD/4-PEG hydrogels show thixotropic behavior and undergo a reversible gel-sol transition in response to shear stress change. We loaded the antiglaucoma drug brimonidine into the α-CD/4-P...

Quick Search